8-K: MoonLake Gains FDA Nod for Sonelokimab BLA in HS

MoonLake Immunotherapeutics received positive FDA feedback, confirming a pathway for Sonelokimab's Biologic License Application in Hidradenitis Suppurativa without additional clinical trials.

Summary

• MoonLake Immunotherapeutics received positive feedback from the U.S. FDA regarding its clinical evidence strategy for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS).
• The FDA confirmed that MoonLake may establish substantial evidence of effectiveness (SEE) for SLK in HS without additional clinical trials.
• The Biologic License Application (BLA) can consist of data from existing VELA-1, VELA-2, and MIRA trials.
• The FDA specifically advised including MIRA trial results for submission and VELA-2 trial results to inform the safety profile, regardless of its utility in establishing SEE.
• MoonLake plans to continue preparations for BLA submission for SLK in HS in H2 2026.
• An Investor Day is scheduled for February 23, 2026, to discuss FDA feedback, value opportunities for SLK in HS, and present new clinical data across indications.
• SLK demonstrated significant improvements in over 1,000 HS patients across MIRA, VELA-1, and VELA-2 trials.
• MIRA trial showed a 43% response with 120mg SLK and a 29 ppt delta vs placebo (p < 0.001) at week 12 using HiSCR75.
• VELA-1 met all primary and key secondary endpoints with statistical significance (35% response with 120mg SLK, delta to placebo of 17ppt, p < 0.001) at Week 16 (HiSCR75).
• VELA-2 achieved statistical significance using the pre-specified treatment policy strategy (36% response with 120mg SLK, delta to placebo of 10ppt, p = 0.033) at Week 16 (HiSCR75), though a higher-than-expected placebo response precluded significance using the primary composite analysis (delta of 9%, p=0.053).
• All trials consistently suggested a favorable safety profile for SLK in HS patients.

Sentiment

Score: 8

Explanation: The positive FDA feedback, confirming a clear regulatory pathway for Sonelokimab in HS without additional trials, is a significant de-risking event and a strong positive for the company. The consistent efficacy and safety data across multiple trials, combined with a clear timeline for BLA submission and upcoming catalysts in other indications, indicates strong progress and future potential.

Positives

• FDA confirmed that substantial evidence of effectiveness (SEE) for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS) can be established using existing VELA-1, VELA-2, and MIRA trial data, eliminating the need for additional clinical trials.
• The FDA's guidance supports MoonLake's perspective on the relevance of MIRA results for the HS BLA submission.
• The BLA submission for SLK in HS remains on track for H2 2026.
• SLK demonstrated significant improvements across key outcomes in over 1,000 HS patients in MIRA, VELA-1, and VELA-2 trials.
• MIRA trial achieved a 43% HiSCR75 response with 120mg SLK, showing a 29 percentage point delta vs placebo (p < 0.001) at week 12.
• VELA-1 met all primary and key secondary endpoints with statistical significance, achieving a 35% HiSCR75 response with 120mg SLK and a 17 percentage point delta to placebo (p < 0.001) at Week 16.
• VELA-2 achieved statistical significance using the pre-specified treatment policy strategy (36% HiSCR75 response with 120mg SLK, delta to placebo of 10 percentage points, p = 0.033) at Week 16.
• All trials consistently indicated a favorable safety profile for SLK in HS patients, with no new safety signals detected in the VELA trials.
• The positive FDA feedback provides clarity and a strong base for broader development of SLK in other indications.

Negatives

• In the VELA-2 trial, a higher-than-expected placebo response precluded the study from achieving statistical significance using the primary composite analysis method for the week 16 primary endpoint (HiSCR75, delta to placebo of 9%, p=0.053).
• The FDA excluded using mechanistic evidence as confirmatory evidence, in combination with results from a single clinical trial, to establish SEE for the HS indication.

Risks

• Interim data analyses conducted prior to database lock and based on a limited number of patients having reached the relevant time point may not be consistent with final data.
• Risks and uncertainties associated with MoonLake's business in general and its limited operating history.
• Difficulty enrolling patients in clinical trials.
• State and federal healthcare reform measures could result in reduced demand for MoonLake's product candidates.
• Reliance on third parties to conduct and support its preclinical studies and clinical trials.
• Actual results could differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

MoonLake Immunotherapeutics plans to submit a Biologic License Application (BLA) for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS) in H2 2026, following positive FDA feedback that allows for submission without additional clinical trials. The company anticipates a catalyst-rich roadmap over the next 12 months, including primary endpoint readouts for the Phase 2 S-OLARIS trial in axSpA (Q1 2026), 52-week data from VELA-1 and VELA-2 in HS (Q2 2026), primary endpoint readouts for Phase 3 IZAR-1 in PsA (Mid 2026), Phase 3 VELA-TEEN in adolescent HS (Mid 2026), and Phase 3 IZAR-2 in PsA (H2 2026). The company also expects to continue the broader development of SLK in other indications.

Management Comments

• "The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required." Dr. Jorge Santos da Silva, Founder and CEO.
• "The fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients." Dr. Jorge Santos da Silva, Founder and CEO.
• "Overall, this also provides a strong base for MoonLake to continue the broader development of SLK in other indications." Dr. Jorge Santos da Silva, Founder and CEO.
• "The FDA has provided us with clear and helpful feedback indicating that the MIRA and VELA trials, which together enrolled more than 1000 patients with moderate-to-severe HS and tested sonelokimab using similar study designs, provide a basis for BLA submission." Prof. Kristian Reich, Founder and CSO.
• "The FDA recognizes that MIRA and VELA-1, which met their primary and important key secondary endpoints, together with VELA-2, can be used to establish substantial evidence of effectiveness, and that VELA-2 provides a key source of evidence to inform, for example, the safety of sonelokimab." Prof. Kristian Reich, Founder and CSO.
• "The encouraging feedback matches our view of the strong performance of sonelokimab in HS across three trials and we are looking forward to further engaging with the FDA prior to the BLA submission." Prof. Kristian Reich, Founder and CSO.

Industry Context

The positive FDA feedback for Sonelokimab in Hidradenitis Suppurativa (HS) positions MoonLake Immunotherapeutics favorably in the competitive inflammatory disease market. HS affects an estimated 2% of the population, with a projected market opportunity of $15 billion by 2035, indicating a significant unmet need for improved treatment options. Sonelokimab, a Nanobody inhibiting IL-17A and IL-17F, targets a key pathway in HS pathogenesis, aligning with increasing scientific evidence. This development could enhance MoonLake's competitive standing against existing and emerging therapies for HS and other inflammatory conditions like psoriatic arthritis and axial spondyloarthritis, where IL-17 pathway inhibitors are also relevant.

Comparison to Industry Standards

• Sonelokimab's mechanism of action, inhibiting IL-17A and IL-17F, targets a pathway recognized as a key driver in the pathogenesis of HS, similar to other IL-17 inhibitors in the broader inflammatory disease market.
• The MIRA trial's HiSCR75 response of 43% with 120mg SLK and a 29 ppt delta vs placebo (p < 0.001) at week 12 demonstrates a strong efficacy profile, which can be compared to other approved HS treatments like adalimumab (Humira) or secukinumab (Cosentyx), though direct head-to-head data against all competitors is not provided in this filing.
• The VELA-1 trial's HiSCR75 response of 35% with 120mg SLK and a 17 ppt delta to placebo (p < 0.001) at Week 16 also indicates robust efficacy.
• The VELA-2 trial's statistical significance using the pre-specified treatment policy strategy (36% HiSCR75 response with 120mg SLK, delta to placebo of 10ppt, p = 0.033) at Week 16, despite a higher-than-expected placebo response in the primary composite analysis, suggests a consistent treatment effect.
• The consistent favorable safety profile across all trials is a critical factor for market differentiation, especially when compared to the known side effect profiles of other biologics.
• The inclusion of a risankizumab active reference arm in the IZAR-2 PsA trial indicates a direct comparison against a known IL-23 inhibitor, which is a common strategy in Phase 3 trials to benchmark efficacy against established therapies.

Stakeholder Impact

• Shareholders: Positive impact due to de-risked regulatory pathway, accelerated potential market entry for SLK in HS, and a strong pipeline of upcoming clinical data readouts, potentially increasing company valuation.
• Patients (HS): Potential for a new, effective treatment option (Sonelokimab) for a debilitating chronic condition with significant unmet need, offering improved outcomes.
• Employees: Positive impact from clear strategic direction and progress towards commercialization, potentially leading to growth opportunities.
• Regulatory Authorities (FDA): Successful engagement and clear guidance provided, demonstrating effective communication and regulatory compliance.

Next Steps

• Continue planned preparations for Biologic License Application (BLA) submission for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS).
• Hold an Investor Day on February 23, 2026, to discuss FDA feedback, value opportunities for SLK in HS, and present new clinical data across indications.
• Announce details for the Investor Day in due course.
• Provide further details on the catalyst calendar for 2026 and beyond.
• Primary endpoint readout of the Phase 2 S-OLARIS trial in Axial Spondyloarthritis (axSpA) in Q1 2026.
• Release 52-week data of the VELA-1 and VELA-2 trials in HS in Q2 2026.
• Primary endpoint readout of the Phase 3 IZAR-1 trial in Psoriatic Arthritis (PsA) in Mid 2026.
• Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HS in Mid 2026.
• Submission of a BLA for SLK in HS in H2 2026.
• Primary endpoint readout of the Phase 3 IZAR-2 trial in PsA in H2 2026.

Key Dates

Recommendation

The FDA's confirmation that MoonLake can submit a Biologic License Application for Sonelokimab in Hidradenitis Suppurativa without requiring additional clinical trials is a highly significant de-risking event. This accelerates the potential market entry for a drug targeting a large and underserved market ($15bn by 2035). The existing clinical data from MIRA, VELA-1, and VELA-2 trials consistently demonstrate strong efficacy and a favorable safety profile. The clear regulatory pathway, coupled with a robust pipeline of upcoming catalysts in other indications (PsA, axSpA, adolescent HS), positions MoonLake for substantial growth. The company's ability to leverage existing data for BLA submission, rather than incurring the time and cost of new trials, represents a major competitive advantage and indicates strong future potential.

Keywords

Sonelokimab, SLK, Hidradenitis Suppurativa, HS, FDA, BLA, Biologic License Application, VELA-1, VELA-2, MIRA, clinical trials, biotechnology, inflammatory diseases, Nanobody, IL-17A, IL-17F, Psoriatic Arthritis, PsA, Axial Spondyloarthritis, axSpA, Palmoplantar Pustulosis, PPP, clinical-stage, drug development, regulatory approval